HR 3029: To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.

HR 3029 in plain English: This bill requires the National Institute of Standards and Technology (NIST) to develop best practices and technical standards for nucleic acid synthesis screening to reduce biosecurity risks, such as the accidental or intentional creation of dangerous biological agents. It also directs NIST to convene stakeholders, report findings to Congress, and advance risk management standards related to engineering biology and artificial intelligence. The bill authorizes $5,000,000 per year for fiscal years 2027 through 2031 for these activities.

Stated purpose

This bill requires the National Institute of Standards and Technology (NIST) to develop best practices and technical standards for screening nucleic acid synthesis, in order to reduce the risk that this technology is misused to create dangerous biological agents.

Key points

• Requires NIST to develop biosecurity best practices and technical standards for nucleic acid synthesis screening
• Directs NIST to convene stakeholders to build consensus on synthetic nucleic acid screening priorities and periodically update them
• Requires NIST to submit a summary of stakeholder findings to Congress
• Directs NIST to advance risk management standards for engineering biology, including AI-related risks
• Authorizes $5,000,000 per year for fiscal years 2027 through 2031 to carry out these activities

Arguments supporters make

• Synthetic DNA and RNA can be ordered and used to engineer dangerous pathogens, so setting clear national screening standards helps close a real biosecurity gap before it is exploited.
• Giving NIST a clear legal mandate and dedicated funding ensures this work actually happens and does not get deprioritized, building on an executive order that was already moving in this direction.
• Bringing together industry, universities, and nonprofits in a consensus-building process means the resulting standards are more likely to be practical, widely adopted, and effective.

Arguments opponents make

• Mandating government-developed standards could slow down legitimate biomedical research and innovation by adding compliance burdens to companies and labs that pose no real threat.
• NIST developing standards through a multi-stakeholder consortium is a slow, bureaucratic process that may produce guidelines too vague or outdated to keep up with rapidly advancing biotechnology.
• Authorizing $5 million per year may be either wasteful if the standards are not enforced or inadequate if the biosecurity challenge is as serious as the bill implies, raising questions about whether this approach is the right scale of response.

Tradeoffs

Tighter screening standards may reduce the risk of dangerous misuse of synthetic biology tools, but could also slow legitimate research and place new compliance costs on biotech companies; the bill attempts to balance these by setting standards through an industry-inclusive process rather than direct regulation.

Current status in Congress: Passed House.

NewsClear — neutral news & congressional tracking · Bill of the Week